All
Women With Advanced Ovarian Cancer See Improved Survival With HIPEC
February 6th 2018Women with newly diagnosed stage III epithelial ovarian cancer experienced an improvement in relapse-free survival and overall survival with the addition of hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery, according to results from a multicenter, open-label, phase III trial.
Prexasertib Demonstrates Activity in BRCA Wild-Type Ovarian Cancer
February 5th 2018According to results of an open-label, single-center, 2-stage, proof-of-concept phase II study, prexasertib (LY2606368), a cell cycle checkpoint kinase 1 and 2 inhibitor, demonstrated clinical activity and was tolerable in women with measurable, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma.
Patients With AR-Positive TNBC May Benefit From Enzalutamide Treatment
February 5th 2018In findings from the phase II MDV3100-11 study published in the<em> Journal of Clinical Oncology</em>, enzalutamide demonstrated early signs of efficacy in patients with androgen receptor-positive triple-negative breast cancer.
Gray Sheds Light on Considerations When Treating NSCLC With Immunotherapy
February 5th 2018Jhanelle E. Gray, MD, recently shared the treatment considerations and decisions she makes when treating patients with non–small cell lung cancer, with a special focus on immunotherapy. Gray, associate member, Director of Thoracic Clinical Research, Moffitt Cancer Center, Tampa, Florida, explained her treatment decisions based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.
CHOP-RIT Regimen Improves PFS Over R-CHOP in Follicular Lymphoma
February 3rd 2018Progression-free survival was improved by nearly 15% with CHOP-RIT compared with R-CHOP alone in previously untreated patients with follicular lymphoma, according to findings from the phase III SWOG-S0016 trial published in the <em>Journal of Clinical Oncology</em>.
Quality of Life Outcomes Similar With Cabozantinib and Everolimus in RCC
February 2nd 2018Treatment with cabozantinib induced similar quality of life results as treatment with everolimus in patients with advanced renal cell carcinoma, according to results of the randomized, open-label, international phase III METEOR trial.
Bevacizumab/Lomustine Combinations Falls Short in Phase III Glioblastoma Trial
January 31st 2018Treatment with lomustine plus bevacizumab provided a slightly improved progression-free survival, but did not demonstrate an overall survival advantage over treatment with lomustine alone in patients with progressive glioblastoma, according to results of a randomized phase III trial published in the<em> New England Journal of Medicine</em>.
CTCs Superior to PSA in Predicting Overall Survival in mCRPC
January 30th 2018Circulating tumor cell conversion and CTC value ≥ 1 at baseline were superior predictors of overall survival than PSA in men with metastatic castration-resistant prostate cancer, according to an analysis of results from 5 clinical trials.<br />
National Academy of Science to Recognize Four Individuals for Cancer Breakthroughs
January 30th 2018During their 155th annual meeting, to be help April 29, the National Academy of Science (NAS) will award 19 individuals for their extraordinary scientific achievements in a wide range of fields including the physical, biological, and medical sciences.
Lutathera Receives FDA Approval for Treatment of GEP-NETs
January 26th 2018Based on results of the phase III NETTER-1 trial, lutathera (lutetium [177Lu] oxodotreotide) has been approved by the FDA for the treatment of patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Cabozantinib Superior to Everolimus in Treatment of RCC Patients With Bone Metastases
January 26th 2018According to results of a subgroup analysis of the phase III METEOR trial, cabozantinib (Cabometyx) demonstrated a 4.7 month improvement in progression-free survival compared with everolimus (Afinitor) in pretreated patients with advanced renal cell carcinoma with bone metastases at baseline.
Pembrolizumab Elicits Promising Activity in HCC Patients Previously Treated With Sorafenib
January 26th 2018In phase II data reported at the 2018 Gastrointestinal Cancers Symposium, treatment with the PD-1 inhibitor pembrolizumab (Keytruda) elicited promising progression-free survival and overall survival results in patients with advanced hepatocellular carcinoma who received previous treatment with sorafenib.
Rituximab Biosimilar Meets Endpoint in Phase III Follicular Lymphoma Trial
January 25th 2018Pfizer has announced that PF-05280586, a biosimilar for rituximab, has delivered positive top-line results, meeting its primary endpoint for overall response rate in the in the phase III REFLECTIONS B3281006 trial for patients with follicular lymphoma.
Napabucasin/Pembrolizumab Combo Shows Early Signs of Efficacy in mCRC
January 25th 2018According to results reported at the 2018 Gastrointestinal Cancers Symposium, early signs of efficacy were seen with the investigational oral cancer stem cell pathway inhibitor napabucasin (BBI608) combined with the PD-1 inhibitor pembrolizumab (Keytruda) in the first 8 patients enrolled in a multicenter phase I/II trial of patients with metastatic colorectal cancer.
Nivolumab Produces Durable Responses Alone and With Ipilimumab in MSI-H/dMMR mCRC
January 24th 2018According to 2 analyses presented at the 2018 Gastrointestinal Cancers Symposium, data from the CheckMate-142 study support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for the treatment of patients with previously treated DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.
Hicks Named Chief of Gynecologic Oncology at Jersey Shore University Medical Center
January 24th 2018Hackensack Meridian Health has announced that Verda J. Hicks, MD, FACS, FACOG, will serve as its chief of Gynecologic Oncology at Jersey Shore University Medical Center. She will be joined by associates James R. Bosscher, MD, and Karim ElSahwi, MD, to facilitate promising experience and care to the Monmouth, Ocean, and Middlesex counties.
Kathy Albain Named First Huizenga Family Endowed Chair at Loyola University Chicago
January 24th 2018Kathy S. Albain, MD, has been named the inaugural Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine. Funded by Heidi Huizenga, one of Albain’s beholden patients, her husband, and her family, the endowed chair recognizes Albain’s notable contributions as a physician, research, teacher and mentor.
Dose Escalating Regorafenib Superior to Standard Dose in CRC, Study Finds
January 23rd 2018According to findings reported during the 2018 Gastrointestinal Cancers Symposium, a weekly dose-escalation strategy of regorafenib (Stivarga) beginning at 80 mg and ending at 160 mg was found to be superior than the previously standard starting dose of 160 mg in patients with metastatic colorectal cancer.
Survival Improved with Tumor-Treating Fields in Glioblastoma
January 23rd 2018Progression-free survival and overall survival were improved for patients with glioblastoma by adding tumor-treating fields to temozolomide (Temodar), according to a final analysis of results from the EF-14 trial.